B.C.’s Microdermics partners with German firm in microneedle project

Vetter and Microdermics join forces for innovation in drug delivery. From left to right: Dr. Claus Feussner, Senior Vice President Vetter Development Service; Prof. Boris Stoeber, Co-founder and Chief Technical Officer; Grant Campany, President & CEO (both Microdermics); and Dr. David Brett, Team

Microdermics Inc., a Vancouver-based medical device company, is seeking to speed up its development of an alternative to the traditional hypodermic needle by partnering with Vetter, a German provider of aseptic prefilled drug delivery systems.

The market in novel alternatives to needle injections is forecasted to grow rapidly, reaching in excess of 480 million units by 2030, according to a Roots Analysis report. However, companies involved in the development of alternatives to hypodermic needles are often hampered by limited investment in scalable aseptic manufacture at the later phases of development.

Related content


Microdermics has chosen to partner with Vetter in order to overcome this hurdle, according to Grant Campany, president, and CEO of Microdermics, said his company will rely on Vetter’s expertise in working with different drug substances.

“Microdermics is extremely excited to work with a world-class partner like Vetter, since our strategic interests align and their decades of experience and innovation in the fill and finish segment will enable us to accelerate our commercialization strategy,” said Campany. “Vetter’s vast experience with a wide variety of drug substances provides us with an invaluable opportunity for a successful development path for our microneedle drug delivery technology.”

As a leading contract development and manufacturing organization (CDMO), Vetter offers customers a combination of device development and associated drug product manufacturing and packaging services.

Microneedles are a novel technology that can offer promising advantages as an alternative to classical needle injections. Because of the system’s ability to deliver more drugs directly into the body, microneedles are effective in reducing the injectable dose needed to trigger an immune response.

Microdermics’ microneedle technology is commercially scalable. It is capable of “pain-free injections into the pharmacokinetically beneficial intradermal space”, providing improved comfort and treatment to patients, according to the company.

Microdermics has successfully demonstrated the initial safety of its microneedle system and is planning Phase 1 human clinical trials for vaccine and therapeutic delivery, to be initiated in 2017.

Be the first to comment

Leave a Reply

Your email address will not be published.